三年亏损超28亿，罗欣药业“卖子求生”，接盘方竟为零资产公司

Core Viewpoint - Recent asset transactions by Luoxin Pharmaceutical highlight the company's ongoing financial struggles, with significant losses and high debt levels prompting asset sales at steep discounts [1][2][6] Financial Performance - As of September 30, 2025, Luoxin Pharmaceutical's total assets were 12.00 billion, with total liabilities at 4.68 billion, resulting in a debt ratio of 61.65% [2][8] - The company reported a net loss of 1.44 billion for the first three quarters of 2025, following a loss of 14.48 billion in 2022 and 6.39 billion in 2023, totaling over 28 billion in losses over three years [10][11] - The company's cash reserves have drastically decreased from 20.02 billion at the end of 2021 to 3.93 billion by mid-2025, a decline of over 80% [11] Asset Sales - Luoxin Pharmaceutical sold its subsidiary, Lekang Pharmaceutical, for 62.5 million, significantly below its net asset value of 73.24 million and only 15% of its registered capital of 420 million [1][6] - The initial listing price for Lekang was 190 million, but after multiple price reductions, it was sold at a 67% discount [8] Business Challenges - The company's core generic drug business has been severely impacted by policy changes, with revenue from generics accounting for approximately 98% of total income, while the average gross margin in the industry has dropped from 75% in 2020 to about 60% [11] - Luoxin's revenue has plummeted from a peak of 6.48 billion in 2021 to 2.65 billion in 2024, indicating a significant contraction in business scale [10] Innovation and R&D - Despite the financial difficulties, Luoxin's innovative drug, Tegoprazan, has shown promising sales, exceeding 2.7 billion in the first half of 2025, marking a nearly 140% increase [12] - However, the company has reduced its R&D spending from 2.05 billion in 2022 to 0.63 billion in the first three quarters of 2025, indicating a shift towards marketing over research [12][13] - Luoxin plans to raise up to 842.4 million through a private placement to support R&D and working capital, but this funding will take time to materialize [12]